Naltrexone is a prescription medicine used to treat alcohol use disorder (AUD) and to help prevent relapse in opioid use disorder (OUD) after detox. As an opioid receptor antagonist, it blocks opioid effects and can reduce alcohol cravings. Available as daily oral tablets and as a monthly extended‑release injection, it works best alongside counseling and recovery supports. Because naltrexone can precipitate withdrawal in people with opioids in their system and carries liver-related cautions, it requires medical screening and monitoring. In the U.S., naltrexone is prescription‑only; safe access includes in‑person visits or telehealth with licensed clinicians.
Naltrexone is most commonly used for alcohol use disorder (AUD) to reduce heavy drinking days and increase the chance of maintaining sobriety. It does not cause sickness if you drink (unlike disulfiram) but can dampen the rewarding effects of alcohol and diminish cravings, making behavioral change more achievable. Its effectiveness is greatest when paired with counseling, peer support, and practical recovery strategies.
In opioid use disorder (OUD), naltrexone helps prevent relapse after detox by blocking the euphoric and sedating effects of opioids. To avoid precipitated withdrawal, patients must be opioid‑free for a medically determined interval before starting. Extended‑release injectable naltrexone (given monthly) can be useful for those who prefer non‑daily therapy or who want a medication without opioid activity (unlike buprenorphine or methadone).
Some clinicians also discuss low‑dose naltrexone (LDN) for off‑label conditions like fibromyalgia or certain inflammatory conditions. Evidence for LDN remains preliminary; patients should weigh potential benefits against uncertainties in dosing and long‑term data with a qualified clinician.
For alcohol use disorder, a common oral dose is 50 mg once daily. Some prescribers may use alternate schedules (for example, 50 mg daily with supervised higher doses on specific days) based on adherence and tolerability. The extended‑release intramuscular formulation is typically administered as 380 mg once every 4 weeks or monthly into the gluteal muscle by a healthcare professional.
For opioid use disorder, oral naltrexone is generally started at 25 mg as a test dose once the patient is opioid‑free, then increased to 50 mg daily if tolerated. The opioid‑free interval differs by opioid type (often 7–10 days for short‑acting opioids and up to 10–14 days for long‑acting opioids or methadone). Some programs use a naloxone challenge or urine toxicology to confirm readiness. The monthly extended‑release injection is another option after confirming opioid abstinence.
Take oral tablets at the same time daily, with or without food; having a small meal can help reduce nausea. Do not use naltrexone if you have any opioids (including certain cough suppressants, antidiarrheals, or pain medicines) in your system. Wear a medical alert bracelet or carry an alert card stating you take naltrexone, as it impacts emergency pain management.
Never start or adjust naltrexone without professional guidance. Your clinician may order baseline and periodic liver function tests, assess mental health and cravings, and coordinate counseling or mutual‑support referrals.
Liver health: Naltrexone can increase liver enzymes; the risk rises with higher doses. People with acute hepatitis or liver failure should not take it. Those with chronic liver disease may still be candidates, but only with careful monitoring. Report symptoms such as right‑upper abdominal pain, dark urine, jaundice, or severe fatigue.
Opioid exposure: Starting naltrexone while opioids are present can precipitate severe withdrawal. Disclose all prescription, over‑the‑counter, and nonmedical opioid use to your clinician. If you need surgery or emergency pain control while on naltrexone, opioids may be less effective; non‑opioid strategies are typically prioritized, and higher levels of care may be required if opioid analgesia becomes necessary.
Mental health: Some people may experience mood changes, anxiety, irritability, or insomnia. Severe depression or suicidal thoughts are uncommon but require prompt medical attention. Let your clinician know your psychiatric history and any changes in mood.
Other considerations: Use caution in moderate to severe renal impairment. Safety and efficacy are established primarily in adults; discuss risks and benefits during pregnancy or breastfeeding. For those at risk of relapse, understand that tolerance to opioids is reduced during and after naltrexone treatment—attempting to “override” the blockade or returning to prior opioid doses can markedly increase overdose risk.
Do not use naltrexone if you have: current opioid use or physiological opioid dependence; a positive opioid screen or opioid withdrawal; acute hepatitis or liver failure; prior severe hypersensitivity to naltrexone or formulation components. Always inform your clinician about implanted opioid devices (e.g., intrathecal pumps) or recent opioid antagonist challenges.
Common side effects include nausea, headache, dizziness, fatigue, abdominal discomfort, decreased appetite, and sleep disturbances (insomnia or drowsiness). These often improve over days to weeks. Taking tablets with food, staying hydrated, and adjusting the time of day may help.
Less common effects include anxiety, irritability, muscle or joint aches, rashes, and increased liver enzymes. Seek care if you develop persistent abdominal pain, dark urine, yellowing skin or eyes, severe vomiting, or profound fatigue, as these may signal liver injury. Allergic reactions are rare but can include hives, facial swelling, wheezing, or anaphylaxis—call emergency services for severe reactions.
For the extended‑release injection, expect possible injection‑site pain, swelling, induration, bruising, or pruritus. Rare but serious complications include injection‑site infections or necrosis; seek medical help for intense pain, warmth, swelling, or drainage. The injection should be given only by trained professionals using proper technique.
In OUD, a serious risk is attempting to override the naltrexone blockade by taking large amounts of opioids, which can lead to overdose once the blockade wanes or if extremely high doses are used. After stopping naltrexone, reduced tolerance further elevates overdose risk—carry naloxone if you are at risk and educate close contacts on its use.
Opioids and opioid‑containing medicines (prescription pain relievers, some cough syrups like codeine‑containing products, and antidiarrheals such as loperamide at misuse doses) will have reduced or blocked effects while on naltrexone and can precipitate withdrawal if taken together. Inform dentists, surgeons, and emergency clinicians that you are taking naltrexone before any procedure.
Because naltrexone is not a significant CYP enzyme inhibitor or inducer, major pharmacokinetic interactions are uncommon. However, use caution with other potentially hepatotoxic agents, such as high‑dose acetaminophen, isoniazid, or excessive alcohol. Combining naltrexone with disulfiram can increase hepatic risk; close monitoring is advisable if both are used for AUD.
Always provide a full medication and supplement list, including herbal products. If opioid analgesia is anticipated (e.g., planned surgery), coordinate with your care team well in advance to develop a pain management plan that may include non‑opioid medications, regional anesthesia, or adjusted timing of naltrexone.
If you miss an oral dose, take it when you remember unless it is close to the next dose—do not double up. Establish reminders or pill organizers to support adherence. If you miss or delay a monthly injection, contact your clinic to reschedule as soon as possible to maintain blockade and reduce relapse risk.
Naltrexone overdose is uncommon but may cause nausea, vomiting, abdominal pain, dizziness, and lethargy. Very high doses can increase hepatic risk. There is no specific antidote; treatment is supportive. If an overdose is suspected, contact poison control or seek emergency care promptly. Never attempt to self‑escalate doses beyond what your prescriber recommends.
Store tablets at room temperature (about 68–77°F or 20–25°C), away from excessive heat, moisture, and light. Keep in the original bottle with the cap tightly closed, out of reach of children and pets. Extended‑release injection vials should be kept in their original carton, protected from light, and stored per label instructions; do not freeze. Follow clinic guidance for transport and handling.
In the United States, naltrexone is a prescription‑only medication. It is not legal to buy naltrexone without a valid prescription from a licensed clinician. Websites or individuals offering prescription drugs without a prescription may be unsafe or unlawful. For your safety, obtain naltrexone only through legitimate pharmacies and care teams.
Access pathways include primary care, addiction medicine specialists, and telehealth programs that provide same‑week evaluations, lab testing when indicated, and ongoing monitoring. Many health systems—such as Geisinger‑affiliated programs—offer structured, lawful care models that streamline evaluation and prescribing while integrating counseling, peer support, and relapse‑prevention planning. These services ensure the screening needed to avoid precipitated withdrawal, monitor liver function, and tailor the regimen to your goals.
If you see “buy Naltrexone without prescription” claims, treat them as red flags. Instead, schedule an appointment (in‑person or via telemedicine) with a licensed clinician, ask about insurance coverage and medication assistance programs, and use pharmacies verified by state boards or the National Association of Boards of Pharmacy. This approach protects your health, ensures legal compliance, and connects you with the behavioral supports that make naltrexone most effective.
Naltrexone is an opioid receptor antagonist that blocks mu-opioid receptors in the brain. By preventing opioids from binding, it removes the “reward” from opioid use and dampens alcohol’s reinforcing effects, helping reduce cravings and relapse risk. It is not an opioid, not a sedative, and not addictive.
Naltrexone is FDA-approved for alcohol use disorder (AUD) and for preventing relapse in opioid use disorder (OUD) after detox. It may reduce heavy drinking days, cravings, and the risk of returning to opioid use. Other uses (such as low-dose naltrexone for pain) are off-label and investigational.
People who are motivated to reduce or stop alcohol use or who have completed opioid detox and want a non-opioid medication option are good candidates. Reliable follow-up, the ability to avoid opioids, and acceptable liver function tests improve success. It works best when combined with counseling and recovery supports.
Do not start naltrexone if you are currently using opioids, have opioids in your system, or depend on opioid pain medicines, because it can precipitate withdrawal. It is contraindicated in acute hepatitis or liver failure and in those with a known hypersensitivity to naltrexone. Caution is needed in significant liver disease and when regular opioid analgesia is anticipated.
Oral naltrexone is usually 50 mg daily (or alternative schedules) and can be started after confirming opioid-free status. Extended-release naltrexone (Vivitrol) is a 380 mg intramuscular injection given once monthly, providing continuous receptor blockade. Choice depends on preference, adherence, access, cost, and clinical factors.
Most people need to be opioid-free for at least 7–10 days after short-acting opioids and 10–14 days or longer after methadone or other long-acting opioids. A clinician may use a naloxone or low-dose naltrexone challenge to confirm readiness. Starting too soon can trigger severe precipitated withdrawal.
Yes. Naltrexone decreases the rewarding effects of alcohol and has been shown to reduce heavy drinking days and cravings, especially when paired with behavioral therapy. It can support both harm reduction (fewer heavy-drinking days) and abstinence goals, depending on the treatment plan.
Common effects include nausea, headache, dizziness, fatigue, insomnia, anxiety, and abdominal discomfort; these often improve over time. The injection can cause site reactions such as pain, swelling, or induration. Rarely, liver enzyme elevations occur; very rarely, serious liver injury has been reported.
Naltrexone can raise liver enzymes in a dose-related manner, so baseline and periodic liver function testing are recommended. It should not be used in acute hepatitis or liver failure. In stable mild-to-moderate liver disease, clinicians may still use it with monitoring if benefits outweigh risks.
You can physically drink, but naltrexone reduces alcohol’s rewarding effects and can help you drink less or not at all. It is not a license to drink more and does not prevent intoxication or impairment. Combining it with counseling improves outcomes.
Tell every clinician you take naltrexone, and consider wearing a medical alert. Non-opioid pain strategies (acetaminophen, NSAIDs, regional anesthesia, ketamine, gabapentinoids) are preferred. If opioids are absolutely necessary in an emergency, higher monitored doses may be needed, and hospital-level care is recommended.
Naltrexone is not addictive, causes no euphoria, and is not a controlled substance. Stopping it does not cause withdrawal, but your opioid tolerance may be reduced, increasing overdose risk if you relapse to opioid use. Ongoing recovery supports are essential.
LDN typically refers to 0.5–4.5 mg daily, far lower than addiction-treatment doses. It is used off-label for certain chronic pain and inflammatory conditions, with emerging but mixed evidence. LDN is not an approved treatment for OUD or AUD at those doses and should not be combined with opioids.
Duration is individualized. Many people with OUD benefit from at least 6–12 months or longer, while people with AUD may use it for months to years based on goals and response. Regular check-ins guide adjustments or discontinuation.
Data are limited. For OUD, buprenorphine or methadone are typically preferred during pregnancy; starting naltrexone is usually avoided unless benefits clearly outweigh risks. For AUD, nonpharmacologic approaches are emphasized; discuss risks and benefits with a specialist for both pregnancy and breastfeeding.
Therapeutic doses of opioids will have little to no effect because receptors are blocked, which can lead to people taking dangerously high amounts trying to overcome the blockade. This is unsafe and can cause overdose when the blockade wanes. Avoid all opioids unless instructed by a clinician.
Both are opioid antagonists, but naloxone is fast-acting and used to reverse opioid overdose, lasting 30–90 minutes. Naltrexone is longer-acting and used for maintenance treatment to prevent relapse, not for emergencies. Naloxone treats overdose; naltrexone supports recovery.
Neither is universally “better”; they suit different needs. Buprenorphine (a partial agonist) can be started without full detox and often has higher retention; naltrexone requires complete detox and suits those who prefer non-opioid therapy or must avoid agonists. Access, adherence, goals, and medical factors guide the choice.
Methadone is a full opioid agonist with robust evidence and high retention but requires specialized clinics and daily dosing initially. Naltrexone is an antagonist available in office settings and monthly injections but demands opioid abstinence before initiation. The best option depends on clinical profile, preferences, and availability.
Vivitrol is a brand of extended-release injectable naltrexone given monthly. Oral naltrexone is the same active ingredient taken as a daily tablet. The injection aids adherence and provides steady blockade; the tablet offers flexibility and lower upfront cost.
Both help AUD but work differently. Naltrexone reduces alcohol reward and heavy drinking; acamprosate helps maintain abstinence by modulating glutamate and is dosed three times daily, primarily cleared by the kidneys. Choice depends on drinking goals, liver and kidney function, adherence, and side-effect profiles.
Disulfiram causes an aversive reaction if alcohol is consumed and works best with supervised dosing and a strict abstinence goal. Naltrexone reduces cravings and heavy drinking risk without causing an aversive reaction. Naltrexone has broader evidence for reducing heavy drinking; both can affect the liver and require monitoring.
Both are opioid antagonists; nalmefene is approved in some countries for as-needed dosing before drinking to reduce alcohol intake. Naltrexone is FDA-approved in the U.S. for daily use in AUD and for OUD relapse prevention, with wider availability. Side effects overlap, with nausea and dizziness common.
Oral: flexible, lower cost, easy to stop, but daily adherence can be challenging and missed doses reduce protection. Injection: monthly adherence, steady levels, reduced “white-knuckle” periods, but higher cost, injection-site reactions, and cannot be quickly reversed. Patient preference and access are key.
Contrave combines naltrexone and bupropion for chronic weight management; it is not for AUD or OUD. Standalone naltrexone is used for AUD/OUD, not weight loss. Contraindications and side effects differ; discuss goals, cardiovascular risk, seizure risk, and medication interactions with your clinician.
Clonidine and lofexidine reduce autonomic withdrawal symptoms short term but do not prevent relapse. Naltrexone is started after detox to block opioids and support relapse prevention. They can be used sequentially: clonidine/lofexidine for detox, naltrexone for ongoing maintenance.
LDN uses very small doses (about 0.5–4.5 mg) for off-label pain and inflammatory conditions, with proposed effects on glial cells and endorphins; evidence is still evolving. Standard doses (oral 50 mg, injection 380 mg monthly) are evidence-based for AUD and OUD. LDN does not provide reliable opioid blockade and should not be used for OUD/AUD.
Suboxone is a partial agonist/antagonist combo that reduces cravings and withdrawal with strong evidence and good retention; it can be started without full detox. Naltrexone is an antagonist requiring complete detox, useful for those preferring a non-opioid option or under legal/professional constraints. Coverage, access, risk tolerance, and treatment goals guide the decision.